Menu
Back to User profile » Dr Maju Mathews
Papers published by Dr Maju Mathews:
Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression
Morrens J, Mathews M, Popova V, Borentain S, Rive B, Gonzalez Martin Moro B, Jamieson C, Zhang Q
Neuropsychiatric Disease and Treatment 2022, 18:1127-1132
Published Date: 7 June 2022
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
Borentain S, Williamson D, Turkoz I, Popova V, McCall WV, Mathews M, Wiegand F
Neuropsychiatric Disease and Treatment 2021, 17:3459-3470
Published Date: 30 November 2021
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
Li G, Keenan A, Daskiran M, Mathews M, Nuamah I, Orman C, Joshi K, Singh A, Godet A, Pungor K, Gopal S
Patient Preference and Adherence 2021, 15:2239-2248
Published Date: 2 October 2021
Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials
Diekamp B, Borentain S, Fu DJ, Murray R, Heerlein K, Zhang Q, Schüle C, Mathews M
Neuropsychiatric Disease and Treatment 2021, 17:2347-2357
Published Date: 15 July 2021
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
Lambert M, Sanchez P, Bergmans P, Gopal S, Mathews M, Wooller A, Pungor K
Neuropsychiatric Disease and Treatment 2020, 16:3197-3208
Published Date: 23 December 2020
Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, Gopal S
Patient Preference and Adherence 2020, 14:1093-1102
Published Date: 2 July 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Neuropsychiatric Disease and Treatment 2020, 16:1533-1542
Published Date: 19 June 2020
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M
Neuropsychiatric Disease and Treatment 2020, 16:681-690
Published Date: 6 March 2020
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Neuropsychiatric Disease and Treatment 2019, 15:1365-1379
Published Date: 21 May 2019
Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E
Neuropsychiatric Disease and Treatment 2019, 15:731-737
Published Date: 22 March 2019
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
Mathe}ws M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Neuropsychiatric Disease and Treatment 2018, 14:2807-2816
Published Date: 25 October 2018
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
Li H, Li Y, Feng Y, Zhuo J, Turkoz I, Mathews M, Tan W
Neuropsychiatric Disease and Treatment 2018, 14:1107-1117
Published Date: 26 April 2018
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Neuropsychiatric Disease and Treatment 2017, 13:2193-2207
Published Date: 17 August 2017